Four Independent Sources in Seven Days

Jan 28 - Feb 4: Four companies across the IT supply chain independently reported memory chip supply tightness:

  1. AVT (distributor, Jan 28): "Lead times trending higher...spot price increases in memory, storage...supply dynamics suggest upward pricing pressure across many technologies going forward"

  2. SSNLF (Samsung, Jan 29): "Customers actively securing supply due to concerns...possible memory shortage, leading disruption end products"

  3. LTRX (Lam Research): WFE guidance shows memory capex constraints

  4. PLUS (IT solutions, Feb 4): "Worldwide shortage of memory chips due to demand for AI-ready products, causing rapid price increases across many IT products"

Signal strength: Pattern compressed from weeks to days. When distributor (AVT), manufacturer (SSNLF), equipment supplier (LTRX), and solutions provider (PLUS) all report the same dynamic within 7 days, it's structural, not idiosyncratic.

PLUS 10-Q: Pricing Power Evidence

Management commentary (lines 1302-1310, filed Feb 4, 2026):

"There is a worldwide shortage of memory chips due to the demand for AI-ready products, which is also causing rapid price increases across many IT products. Like others, we may experience ongoing supply constraints for memory chips that may affect lead times for delivery of products, our having to carry more inventory for longer periods, our and the customer's costs of products...Despite these actions, we believe extended lead times and price increases will likely persist for at least the next few quarters."

Translation: Price increases and extended lead times through at least Q1-Q2 2026, likely into H2.

Q3 FY2026 financials (filed Feb 4):

  • Revenue: $614.8M (+24.6% YoY)
  • Gross margin: 25.8% (+40bps YoY expansion during shortage)
  • Operating income: $43.5M (+164% YoY), margin 7.1% (+380bps)
  • EPS: $1.27 vs $0.55 PY (+131%)

Working capital surge:

  • Inventory: $241M (+$120M from March) — pre-buying during shortage
  • AR: +$184M (payment terms + 24% revenue growth)
  • Operating cash flow: -$223M vs +$187M PY (growth investment, not distress)

Pricing power thesis: Distributors with inventory during supply shortage can pass through price increases. PLUS showing +40bps gross margin expansion during shortage = evidence of pricing power, not just revenue pass-through.

Why This Matters

1. Stock underperformance vs fundamentals:

  • Current price: $86.09 (+7% YTD)
  • Operating income: +164% YoY
  • Analyst target: $108 (+25.5% upside, Stifel single analyst)

Market hasn't priced shortage pricing power. Stock lagging fundamentals by 15× (7% vs 164%).

2. Thin coverage = potential overlooked opportunity:

  • 1 analyst covering (Stifel)
  • Market cap: $2.3B (not micro-cap, but under-followed)
  • Coverage gap suggests market may be missing the margin expansion story

3. AI infrastructure demand broadening: Lines 1234-1236: "AI continues to be a transformative force and demand driver particularly for our core products: Compute, Cloud, security, networking and our consultative services."

Not just HBM for AI chips — conventional servers, networking, storage all seeing AI-driven pull. PLUS positioned at the distribution layer where shortage pricing power accrues.

Critical Gaps

1. Factor decomposition incomplete:

  • From yfinance: PLUS has 31.7% idio vol (vs CDW 24.0%)
  • But need full regression: How much return is SPY + XLK + SOXX vs orthogonal alpha?
  • Without this: Can't size confidently. If <60% idio, no edge in realized factors.

2. Peer comparison missing:

  • PLUS gross margin: 25.8% (+40bps YoY)
  • CDW, TD SYNNEX margins: Unknown from filing
  • Without this: Can't tell if PLUS outperforming or in-line with sector
  • If peer margins also expanding +40bps → sector beta, not PLUS-specific edge

3. Inventory positioning unclear:

  • $241M inventory (+$120M) positioned as "strategic pre-buying"
  • But risk: Slow-moving dead stock if demand reverses
  • Need verification: Inventory turnover vs historical, days on hand trend

4. Shortage duration ambiguous:

  • Management: "at least the next few quarters"
  • Does that mean Q1-Q2 2026 (transient, 6-month trade) or extends into H2 (structural, 12-month hold)?
  • Without clarity: Sizing timeline unclear

5. Pricing pass-through unverified:

  • Filing mentions "pricing arrangements we have with our customers" as risk (line 113)
  • Are contracts fixed-price (can't pass through) or variable (can pass through)?
  • Without verification: Pricing power thesis could be wrong

Likelihood Ratio: 1.8 (Moderately Bullish)

Justified by current evidence:

BULL CASE (+):

  • Cross-ticker convergence (4 sources in 7 days) = signal strength high
  • Gross margin expansion (+40bps) during shortage = pricing power evidence
  • Operating leverage exceptional (7.1% margin vs 3.3% PY)
  • Stock underperformance vs fundamentals (+7% vs +164% op income) = market hasn't priced it
  • Thin coverage (1 analyst) + analyst upside (+25.5%) = overlooked opportunity

BEAR CASE (-):

  • Factor decomp incomplete: Unknown how much return is idio vs sector beta
  • Peer comp missing: Unknown if margin expansion is PLUS-specific or sector-wide
  • Shortage duration unclear: 6-month transient vs 12-month structural determines upside
  • Inventory risk: $241M could be dead stock if demand reverses
  • Pricing pass-through unverified: Contracts may be fixed-price

Why 1.8 (not higher):

  • Cross-ticker convergence strong, but gaps prevent confident sizing
  • Margin expansion is evidence, but peer context missing
  • Shortage timeline ambiguity prevents position duration clarity

Why 1.8 (not lower):

  • Four independent sources in 7 days is real signal, not noise
  • Stock lagging fundamentals by 15× suggests misprice
  • Operating leverage (7.1% margin) beyond revenue growth = operational efficiency

Verdict

LR = 1.8 justified by convergence + margin expansion evidence.

Escalation rationale:

  1. Pattern strength increasing (7-day window compression)
  2. Stock underperformance vs fundamentals material (+7% vs +164%)
  3. Thesis-dependent gap: Is shortage transient (6mo) or structural (12-18mo)?

Not a clear buy because gaps prevent confident sizing:

  • Without factor decomp: Can't determine if <60% idio (no edge) or >75% idio (strong edge)
  • Without peer comp: Can't determine if margin expansion is PLUS-specific alpha or sector beta
  • Without shortage timeline: Can't determine position duration (6mo trade vs 12mo hold)

Position constraint: Max 2% until gaps filled. LR=1.8 warrants exposure, but gaps limit sizing confidence.

Next Steps (If Pursuing)

Must do before sizing >2%:

  1. Factor regression: PLUS vs SPY + XLK + SOXX. What % is idio? (Target >75%)
  2. Peer comp: CDW, TD SYNNEX gross margin trends. Is +40bps outperformance or in-line?
  3. Shortage timeline synthesis: ASML, LRCX, MU guidance on DRAM supply normalization. Q2 2026 or H2?

Should do for risk management: 4. Inventory analysis: Turnover ratio vs historical, days on hand trend 5. Contract review: Prior 10-Ks for customer pricing arrangement details

Decision tree:

  • If idio >75% AND peer outperformance AND shortage extends H2 2026: → Size 4-5% (proportional to edge % × conviction)

  • If idio 60-75% OR peer in-line OR shortage resolves Q2: → Size 2-3% (moderate conviction, shorter duration)

  • If idio <60% AND no peer outperformance: → Pass (no edge, just sector beta)